Crossmark

In reply: Why remifentanil?

Crossref DOI link: https://doi.org/10.1007/s00540-018-2487-7

Published Online: 2018-04-03

Published Print: 2018-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sakai, Wataru

Yoshikawa, Yusuke

Yamakage, Michiaki
License Information

Text and Data Mining valid from 2018-04-03
More Information

Article History

Received: 6 March 2018

Accepted: 18 March 2018

First Online: 3 April 2018

Compliance with ethical standards

:

: The authors declare that they have interest and nothing to disclose.